Oscar Health (NYSE:OSCR) Stock Price Target Cut by Piper Sandler

Oscar Health (NYSE:OSCR) had its target price decreased by analysts at Piper Sandler from $48.00 to $45.00 in a research note issued on Friday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Piper Sandler‘s price target would indicate a potential upside of 35.74% from the company’s current price.

Several other analysts have also recently issued reports on the stock. Raymond James Financial increased their target price on shares of Oscar Health from $34.00 to $42.00 and gave the stock an “outperform” rating in a research note on Friday, September 18th. Barclays upped their target price on Oscar Health from $39.00 to $49.00 and gave the stock an “overweight” rating in a research note on Thursday, September 17th. Wells Fargo & Company raised their price objective on Oscar Health from $20.00 to $27.00 and gave the company an “equal weight” rating in a research note on Thursday, August 13th. The Goldman Sachs Group reissued a “neutral” rating and set a $34.00 price target on shares of Oscar Health in a research report on Thursday, September 17th. Finally, Weiss Ratings raised Oscar Health from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $34.60.

Oscar Health Trading Down 5.8%

Shares of OSCR opened at $33.15 on Friday. The firm has a market cap of $10.23 billion, a P/E ratio of 23.68, a price-to-earnings-growth ratio of 0.39 and a beta of 2.56. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.09 and a current ratio of 1.09. The business has a 50-day moving average of $31.80 and a 200 day moving average of $23.89. Oscar Health has a fifty-two week low of $10.69 and a fifty-two week high of $38.50.

Oscar Health (NYSE:OSCR) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.63. Oscar Health had a net margin of 3.60% and a return on equity of 38.45%. The company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $4.69 billion. During the same quarter in the previous year, the firm posted ($0.53) earnings per share. The company’s quarterly revenue was up 72.1% compared to the same quarter last year. As a group, research analysts forecast that Oscar Health will post 1.83 EPS for the current year.

Insider Buying and Selling at Oscar Health

In related news, CFO Richard Blackley sold 28,869 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $31.45, for a total value of $907,930.05. Following the completion of the transaction, the chief financial officer directly owned 1,046,108 shares in the company, valued at $32,900,096.60. This trade represents a 2.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Adam Mcananey sold 9,092 shares of the stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $31.45, for a total transaction of $285,943.40. Following the completion of the transaction, the insider owned 209,004 shares of the company’s stock, valued at approximately $6,573,175.80. The trade was a 4.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 874,451 shares of company stock valued at $26,761,671. Company insiders own 22.64% of the company’s stock.

Institutional Investors Weigh In On Oscar Health

A number of hedge funds and other institutional investors have recently bought and sold shares of OSCR. Tidal Investments LLC bought a new position in shares of Oscar Health during the second quarter valued at approximately $2,240,000. Genesee Capital Advisors LLC boosted its position in shares of Oscar Health by 227.8% in the 3rd quarter. Genesee Capital Advisors LLC now owns 44,338 shares of the company’s stock worth $1,367,000 after purchasing an additional 30,814 shares in the last quarter. Convergence Investment Partners LLC bought a new stake in shares of Oscar Health in the 1st quarter worth approximately $1,208,000. Wellington Management Group LLP grew its stake in shares of Oscar Health by 65.6% in the 2nd quarter. Wellington Management Group LLP now owns 603,675 shares of the company’s stock worth $17,217,000 after buying an additional 239,109 shares during the last quarter. Finally, AXQ Capital LP purchased a new stake in shares of Oscar Health in the 2nd quarter worth approximately $1,059,000. Hedge funds and other institutional investors own 75.70% of the company’s stock.

Trending Headlines about Oscar Health

Here are the key news stories impacting Oscar Health this week:

• Positive Sentiment: Oscar reported Q3 adjusted earnings of $0.49 per share, versus expectations for a loss, and revenue of $5.14 billion, above the $4.69 billion consensus and up 72.1% year over year. The company also recorded a $167.3 million profit, while membership rose 27.2% to 2.69 million and its medical loss ratio improved to 84%. Oscar Health Q3 2026: A Surprise Profit and Its Third Guidance Raise
• Positive Sentiment: Management raised its 2026 revenue outlook for the third time, to $19 billion–$19.3 billion, above FactSet’s $18.64 billion estimate. The higher forecast signals stronger expected sales than analysts had anticipated. Oscar Health 2026 Revenue Outlook
• Positive Sentiment: Zacks added OSCR to its Rank #1 (Strong Buy) growth-stocks list, adding a favorable analyst-screening signal. Best Growth Stocks to Buy for November 6th
• Neutral Sentiment: Despite the earnings beat and stronger outlook, one report said Oscar shares slipped as other healthcare stocks rose. That points to a mixed immediate reaction, rather than a clear deterioration in the company’s reported results. Oscar slips as LifeStance, HCA climb on earnings, payment hike

Oscar Health Company Profile

Oscar Health, Inc is a technology-focused health insurance company that provides health plans and related services in the United States. The company primarily serves individuals and families purchasing coverage through the Affordable Care Act’s health insurance marketplace, as well as small businesses and their employees.

Oscar combines health insurance products with digital tools designed to help members manage their care. Its services include online enrollment, virtual care, provider search and appointment support, care navigation, claims and benefits information, and member engagement through web and mobile applications.